Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-30

Study Completion Date

2021-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861

Zika Virus

COMPLETED PHASE2

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

NCT03611946

Zika Virus

COMPLETED PHASE1

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626

Virus, Zika Zika Virus Disease Flavivirus Infections +1 more

COMPLETED PHASE1

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

NCT02840487

Prevention of Zika Infection Zika-Specific Immune Response

COMPLETED PHASE1

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

NCT03624946

Zika Virus Infection Zika Virus Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zika Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Observer blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mRNA-1893

Group Type EXPERIMENTAL

mRNA-1893

Intervention Type BIOLOGICAL

Zika vaccine

Placebo

0.9% sodium chloride

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

0.9% sodium chloride

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mRNA-1893

Zika vaccine

Intervention Type BIOLOGICAL

Placebo

0.9% sodium chloride

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Agrees to comply with the study procedures and provides written informed consent
* 18 to 49 years of age
* In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., complete diary cards, return for follow-up visits, be available for safety telephone calls).
* Is in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, and physical examination at screening.
* Negative urine pregnancy test at the Screening visit and at the day of each vaccination for females of childbearing potential.
* Male participants must agree to practice adequate contraception from the time of the first vaccination and through 3 months following the last vaccination.
* For flavivirus-seropositive group, has positive flavivirus test results (including dengue, West Nile, and Zika) as determined by enzyme-linked immunosorbent assay (ELISA) or other commercially available serological assay.
* For flavivirus-seronegative group, has negative flavivirus test results (including dengue, West Nile, and Zika) as determined by ELISA or other commercially available serological assay.

Exclusion Criteria

* Has any acute or chronic, Clinically Significant disease in the opinion of the investigator.
* Has received a vaccine for dengue, Japanese encephalitis, tick-borne encephalitis, West Nile, Yellow Fever, or Zika.
* Has a neurologic disorder
* Has a body mass index that is ≤ 18 or ≥ 35 kg/m2.
* Has elevated liver function tests
* Has clinical laboratory test results (hematology, serum chemistry, or coagulation) with a toxicity score of Grade ≥ 1 at Screening.
* Has a bleeding disorder that would contraindicate IM injections or phlebotomy.
* Reports a diagnosis of congenital or acquired immunodeficiency (including HIV infection), or autoimmune disease.
* Has a history of hypersensitivity or severe reactions to previous vaccinations or any component of the study vaccine.
* Has a history of idiopathic urticaria.
* Reports a previous diagnosis of hematologic malignancy or pre-malignancy or a diagnosis of any other malignancy within the previous 10 years (excluding nonmelanoma skin cancer).
* Has a medical, psychiatric, or occupational condition that, in the opinion of the investigator, might pose an additional risk to the participant due to participation in the study or would interfere with the evaluation of the study vaccines or the interpretation of study results.
* Is acutely ill or febrile on the day of screening (Day 0) or randomization (Day 1).
* Has a history of inflammatory arthritis.
* Has a history of febrile disease with arthritis or arthralgia within 2 weeks of administration of any study vaccine.
* Has received an investigational or nonregistered product (drug or vaccine) within 30 days before the first dose of study vaccine or has plans for administration during the study period.
* Has received or is scheduled to receive an inactivated vaccine within the period from 14 days before, or through 14 days after, administration of any study vaccination.
* Has received or is scheduled to receive a live virus vaccine administered within the period from 28 days before, or through 28 days after, any dose of study vaccine.
* Has received chronic administration (defined as \> 14 total days) of immunosuppressants or other immune-modifying drugs within 6 months before the first study vaccine dose.
* Has received immunoglobulins and/or blood products within the 3 months before the first study vaccine dose or has plans for administration during the study period.
* Has a positive test result at the Screening Visit for hepatitis B surface antigen, hepatitis C virus antibody, or HIV type 1 or 2 antibodies.
* Has donated \> 450 mL of whole blood or blood products within 30 days of enrollment or plans to do so during the study period.
* Is an immediate family member or household member of study personnel.
* Previously participated in an investigational study involving LNPs.
* Has a positive urine drug screen result at Screening for any of the following nonprescription drugs of abuse: amphetamines, benzodiazepines, cocaine, methadone, opiates, and phencyclidine.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes